Paul Gibbons,Emily Hanan,Wendy Liu,Joseph P. Lyssikatos,Steven R. Magnuson,Rohan Mendonca,Richard Pastor,Thomas E. Rawson,Michael Siu,Mark E. Zak,Aihe Zhou,Bing-Yan Zhu,Christopher Hurley
申请号：
US16561432
公开号：
US20200002345A1
申请日:
2019.09.05
申请国别(地区):
US
年份:
2020
代理人:
摘要：
A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
